Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.456, 2004-01, pp. : 3-4
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Insulin analogues worth the extra cost in type 1 DM
Inpharma, Vol. 1, Iss. 1444, 2004-01 ,pp. :
Access to resources
Recommend
Premixed insulin analogues worth it in the long term in type 2 DM
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 490, 2005-01 ,pp. :
Early captopril treatment worth it to prevent ESRD in type 1 DM
Inpharma, Vol. 1, Iss. 1464, 2004-01 ,pp. :
Insulin detemir "good value for money" for type 1 DM in Austria
Inpharma, Vol. 1, Iss. 1519, 2006-01 ,pp. :
Amifostine worth extra cost in treating solid tumours
Inpharma, Vol. 1, Iss. 1281, 2001-01 ,pp. :